Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs low molecular weight heparin for initial anticoagulation in symptomatic lower extremity DVT
ChiCTR2100050798Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Sep 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux and low molecular weight heparin calcium in deep vein thrombosis (DVT) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Incidence of symptomatic recurrent venous thromboembolism. Started Sep 2021; status: recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calcium
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR2100050798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050798.